Get started
Author

Joel A. Cummings

Observed names: J A Cummings, J. A. Cummings, J. Cummings, Joel Cummings
OpenAlex ID: A5074811293
Perlecan Binds to the β‐Amyloid Proteins (Aβ) of Alzheimer's Disease, Accelerates Aβ Fibril Formation, and Maintains Aβ Fibril Stability
1997 · Gerardo M. Castillo, Catherine Ngo, et al. · Journal of Neurochemistry · 272
Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation.
1998 · G M Castillo, J A Cummings, et al. · Diabetes · 131
The Unifying Hypothesis of Alzheimer’s Disease: Heparan Sulfate Proteoglycans/Glycosaminoglycans Are Key as First Hypothesized Over 30 Years Ago
2021 · Alan David Snow, Joel A. Cummings, et al. · Frontiers in Aging Neuroscience · 87
PDF
The Amazon rain forest plant Uncaria tomentosa (cat’s claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques and tangles
2019 · Alan D. Snow, Gerardo M. Castillo, et al. · Scientific Reports · 73
PDF
Localization of perlecan (or a perlecan-related macromolecule) to isolated microglia in vitro and to microglia/macrophages following infusion of beta-amyloid protein into rodent hippocampus
1997 · John D. Miller, Joel Cummings, et al. · Glia · 38
Novel Purification and Detailed Characterization of Perlecan Isolated from the Engelbreth-Holm-Swarm Tumor for Use in an Animal Model of Fibrillar A Amyloid Persistence in Brain
1996 · G. M. Castillo, J. A. Cummings, et al. · The Journal of Biochemistry · 22
P3‐254: Exebryl‐1: A novel small molecule currently in human clinical trials as a disease‐modifying drug for the treatment of Alzheimer's disease
2009 · Alan D. Snow, Joel Cummings, et al. · Alzheimer s & Dementia · 18
In vitro comparison of major memory-support dietary supplements for their effectiveness in reduction/inhibition of beta-amyloid protein fibrils and tau protein tangles: key primary targets for memory loss
2021 · Alan D. Snow, Joel A. Cummings, et al. · Scientific Reports · 14
PDF
P2‐529: Identification of Exebryl‐1® and other novel small molecules as tau protein aggregation inhibitors
2011 · Qubai Hu, Judy Cam, et al. · Alzheimer s & Dementia · 5
P2‐310: Exebryl‐1: A novel small‐molecule drug that markedly reduces amyloid plaque load and improves memory, enters human clinical trials
2008 · Alan D. Snow, Joel A. Cummings, et al. · Alzheimer s & Dementia · 2
P4–319: Development of exebryl–1: A disease modifying small molecule therapeutic that causes a marked clearance of brain amyloid load and improved memory in transgenic mouse models of Alzheimer's disease
2006 · Alan D. Snow, Joel A. Cummings, et al. · Alzheimer s & Dementia · 2
PDF
P2‐311: Blood‐brain barrier penetration of a novel disease‐modifying 7‐mer peptide (DP‐74) that reduces brain amyloid plaque load and improves memory in a transgenic mouse model of Alzheimer's disease
2008 · Alan D. Snow, Joel A. Cummings, et al. · Alzheimer s & Dementia · 1
P4–320: Development of novel disease–modifying small peptides that cause a reduction of brain amyloid plaque load and improved memory in a transgenic mouse model of Alzheimer's disease
2006 · Alan D. Snow, Joel A. Cummings, et al. · Alzheimer s & Dementia · 1
Disruption of pre-deposited Alzheimer's aβ 1–42 fibrils by PTI-00703 (cat's claw derivative) in a rodent model of Aβ fibrillogenesis
2000 · Joel A. Cummings, Gerardo M. Castillo, et al. · Neurobiology of Aging · 1
P4‐214: Identification of Novel Small‐molecule Tau Aggregation Inhibitors for Treatment of Tauopathies
2014 · Qubai Hu, Judy Cam, et al. · Alzheimer s & Dementia
O4‐11‐04: Identification of novel small molecules as tau protein aggregation inhibitors
2012 · Judy Cam, Joel Cummings, et al. · Alzheimer s & Dementia
2.315 Identification of potent small molecule inhibitors of alpha-synuclein aggregation in cell culture and by in vitro screening
2007 · A. Snow, L. Esposito, et al. · Parkinsonism & Related Disorders
P4–082: Heparan sulfate proteoglycan accumulation occurs concurrent with beta–amyloid protein plaque deposition in APP transgenic mouse models of Alzheimer's disease
2006 · Joel A. Cummings, Eliezer Masliah, et al. · Alzheimer s & Dementia
P4-327 Potent reduction of microgliosis and astrocytosis in APP transgenic mice brain tissue by PTI-0038
2004 · Joel A. Cummings, Beth P. Nguyen, et al. · Neurobiology of Aging
P4-372 PTI-0038 causes a marked clearance of amyloid plaque burden and improved memory in a transgenic mouse model of Alzheimer's disease
2004 · Alan D. Snow, Joel A. Cummings, et al. · Neurobiology of Aging
P2-123 Alzheimer's amyloid plaque formation induced by sulfated glycosaminoglycans are resistant to degradation by proteases and microglia
2004 · Virginia J. Sanders, Alan D. Snow, et al. · Neurobiology of Aging
Alzheimer's plaques re-created in a test tube: Further insights into the mechanism of amyloid plaque formation
2000 · Alan D. Snow, Joel A. Cummings, et al. · Neurobiology of Aging
627 Localization of perlecan (or an immunologically related proteoglycan) to isolated microglia in vitro and to infiltrating microglia following infusion of beta-amyloid protein into rodent hippocampus
1996 · A.D. Snow, J. Cummings, et al. · Neurobiology of Aging
Works count: 23
Citation count: 667
H-index: 8
I10-index: 8
Year
Topic
Type